What is the appropriate dosing and administration of tenecteplase (TNK) for an adult with acute ischemic stroke presenting within the therapeutic window, including considerations for large‑vessel occlusion?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Tenecteplase in Acute Ischemic Stroke

For adults with acute ischemic stroke presenting within 4.5 hours of symptom onset or last known well, administer tenecteplase 0.25 mg/kg (maximum 25 mg) as a single intravenous bolus over 5-10 seconds. This dose is now the preferred thrombolytic agent, offering equivalent efficacy to alteplase with significantly easier administration 1.

Dosing Algorithm

Standard Dosing (Within 4.5 Hours)

Use tenecteplase 0.25 mg/kg (maximum 25 mg) as a single IV bolus 1:

  • <60 kg: 15 mg (3 mL)
  • 60 to <70 kg: 17.5 mg (3.5 mL)
  • 70 to <80 kg: 20 mg (4 mL)
  • 80 to <90 kg: 22.5 mg (4.5 mL)
  • ≥90 kg: 25 mg (5 mL)

For patients <50 kg with accurate weight, 1-kg band dosing may be used, but do not delay treatment to obtain exact weight—timely administration is critical 1.

Administration Details

  • Route: Intravenous bolus only 2
  • Speed: Push over 5-10 seconds 1
  • Preparation: Reconstitute with supplied sterile water to achieve 5 mg/mL concentration 2

Evidence Base

The 2026 AHA/ASA guidelines provide a Class 1, Level A recommendation for tenecteplase 0.25 mg/kg based on multiple large phase 3 RCTs involving >6,000 patients worldwide 1. These trials consistently demonstrated noninferiority to alteplase for functional outcomes (mRS 0-1 or entire scale at 90 days) with similar safety profiles 1. The practical advantages are substantial: single bolus administration versus a 60-minute infusion reduces dosing errors and treatment delays, potentially shortening door-to-needle times 1.

Large Vessel Occlusion Considerations

For patients with large vessel occlusion (LVO) within 4.5 hours, tenecteplase 0.25 mg/kg is preferred over alteplase 3. Real-world data demonstrates:

  • Higher pre-thrombectomy reperfusion rates: 14.8% vs 4.5% with alteplase (risk difference 10.3%, p=0.008) 4
  • Improved 90-day functional outcomes: 47.3% vs 29.3% achieving mRS 0-2 in LVO patients (p=0.031) 4
  • Better recanalization: OR 3.30 for recanalization compared to control 5, 6

Even in patients proceeding to mechanical thrombectomy, do not skip IVT with tenecteplase—administer it as bridging therapy 3.

Critical Dosing Warning

Do NOT use tenecteplase 0.4 mg/kg 1. This dose carries a Class 3 (No Benefit), Level A recommendation based on multiple trials showing:

  • Increased symptomatic intracranial hemorrhage risk without functional benefit 1
  • The NOR-TEST 2 trial was prematurely terminated due to worse safety and functional outcomes at this dose 1
  • No additional advantages over 0.25 mg/kg with potential for harm 1

Post-Administration Monitoring

After tenecteplase administration 1:

  • Admit to intensive care or stroke unit
  • Neurological assessments and BP monitoring:
    • Every 15 minutes during and for 2 hours after administration
    • Every 30 minutes for next 6 hours
    • Hourly until 24 hours post-treatment
  • Blood pressure control: Maintain SBP ≤180 mmHg and DBP ≤105 mmHg
  • Delay invasive procedures: Avoid nasogastric tubes, bladder catheters, or arterial lines unless absolutely necessary
  • Follow-up imaging: Obtain CT or MRI at 24 hours before starting anticoagulants or antiplatelets

If the patient develops severe headache, acute hypertension, nausea, vomiting, or neurological worsening, obtain emergency head CT immediately 1.

Extended Time Window (4.5-24 Hours)

For patients presenting 4.5-24 hours after last known well, the evidence is more limited. Do NOT use tenecteplase for wake-up stroke or unknown onset selected by non-contrast CT alone 3. However, recent meta-analyses suggest potential benefit in extended windows when:

  • Advanced imaging (perfusion or MRI) demonstrates salvageable tissue
  • Large vessel occlusion is present
  • Mechanical thrombectomy is unavailable 5, 6

This remains an area requiring further study, and current guidelines do not support routine use beyond 4.5 hours without advanced imaging selection 1, 3.

Special Populations

Pediatric patients: Safety and efficacy not established; limited data from 11 children exists but insufficient for recommendations 1

Pregnancy: Myocardial infarction and stroke are medical emergencies—life-sustaining therapy should not be withheld due to pregnancy concerns 2

Practical Implementation Advantages

Tenecteplase offers significant operational benefits over alteplase 1:

  • Simplified dosing: Weight-based bands reduce calculation errors
  • Faster administration: 5-10 second bolus vs 60-minute infusion
  • Reduced treatment delays: Shorter door-to-needle times in real-world practice
  • Easier storage: Single vial system
  • Lower nursing burden: No infusion pump required

These practical advantages translate to faster treatment delivery without compromising safety or efficacy, making tenecteplase the preferred agent in contemporary stroke care 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.